Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Morgan Stanley analyst Manan Gosalia maintains Comerica (NYSE:CMA) with a Equal-Weight and maintains $53 price target.
Truist Securities analyst Brandon King maintains Comerica (NYSE:CMA) with a Buy and lowers the price target from $62 to $60.
Piper Sandler analyst Scott Siefers maintains Comerica (NYSE:CMA) with a Neutral and raises the price target from $53 to $54.
RBC Capital analyst Jon Arfstrom maintains Comerica (NYSE:CMA) with a Outperform and raises the price target from $61 to $62.
UBS analyst Erika Najarian maintains Comerica (NYSE:CMA) with a Neutral and lowers the price target from $59 to $55.
Stephens & Co. analyst Terry McEvoy reiterates Comerica (NYSE:CMA) with a Overweight and maintains $64 price target.
Stocks surged higher on Thursday, with the S&P 500 index aiming to snap a four-day losing streak as investors assess the la...
Companies Reporting Before The Bell • Addex Therapeutics (NASDAQ:ADXN) is estimated to report earnings for its fourth quarter.
Cautious optimism hangs in the air on Thursday morning as index futures traded up moderately in early hours.
